Ravulizumab and eculizumab reduce transfusions in adult patients with paroxysmal nocturnal hemoglobinuria: evidence from three real-world databases: TriNetX us EMR, TriNetX US claims and Komodo Health
Changes in hemoglobin measures observed in PNH patients treated with both c5 inhibitors ravulizumab and eculizumab: real-world evidence from a US-Based EMR network
Designing epidemiological studies to estimate the incidence of thrombosis in patients with antiphospholipid syndrome with history of recurrent thrombotic event
